Geode Capital Management LLC Has $2.34 Million Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Geode Capital Management LLC trimmed its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 3.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 917,367 shares of the biopharmaceutical company’s stock after selling 32,779 shares during the period. Geode Capital Management LLC owned about 1.87% of Puma Biotechnology worth $2,340,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Puma Biotechnology in the 3rd quarter valued at about $34,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Puma Biotechnology in the 3rd quarter valued at $44,000. Patriot Financial Group Insurance Agency LLC increased its position in shares of Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 8,000 shares during the period. Royce & Associates LP lifted its holdings in Puma Biotechnology by 71.8% in the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 8,427 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in Puma Biotechnology in the second quarter valued at approximately $54,000. 61.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on PBYI. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Monday, December 23rd.

Puma Biotechnology Stock Up 5.4 %

Shares of NASDAQ:PBYI opened at $3.74 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average is $3.02 and its 200 day moving average is $2.98. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $7.73. The stock has a market cap of $183.59 million, a price-to-earnings ratio of 7.79 and a beta of 1.10.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the prior year, the company earned $0.12 EPS. On average, sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the completion of the sale, the insider now owns 108,951 shares in the company, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the transaction, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This represents a 0.48 % decrease in their position. The disclosure for this sale can be found here. Insiders own 23.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.